HC Wainwright reaffirms "Buy" rating for Vor Biopharma, setting a $17.50 price target.

HC Wainwright has reaffirmed a "Buy" rating for Vor Biopharma (VOR), setting a price target of $17.50. Other analysts have varied opinions, with Oppenheimer lowering its target to $10, while JMP Securities and Wedbush maintain outperform ratings with targets of $12 and $11, respectively. The consensus price target is $10.92. Vor Biopharma’s lead product, tremtelectogene empogeditemcel, is in phase 1/2 trials for acute myeloid leukemia.

September 10, 2024
4 Articles